$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
NEW YORK, May 18, 2017 -- Cortice Biosciences announced today that final results from the dose-escalation portion of a Phase 1/2 clinical trial evaluating TPI 287 for treatment of recurrent glioblastoma (GBM) will be presented at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, IL. These results will be presented during the Central Nervous System Tumors Poster Session on Monday, June 5, and reviewed during a poster discussion session later that afternoon.
Title: Final results from the dose-escalation stage of a Phase 1/2 trial of TPI 287, a brain penetrable microtubule inhibitor, plus bevacizumab in patients with recurrent glioblastoma
Date: Monday, June 5
Display time: 1:15 – 4:45 PM CDT
Discussion: 4:45 – 6:00 PM CDT
Abstract #: 2021
Presenter: Samuel Goldlust, M.D., John Theurer Cancer Center, Hackensack, NJ
About TPI 287
TPI 287 is a novel taxoid which binds to and stabilizes the assembly of microtubules similarly to commonly used taxanes, including paclitaxel (Taxol® and Abraxane®) and docetaxel (Taxotere®). In oncology treatment settings, microtubule stabilization by these agents leads to mitotic arrest and cancer cell death. TPI 287 has advantages over these taxanes for the treatment of brain cancers due to its ability to penetrate the central nervous system, which is often shielded from systemic administration of other anti-cancer drugs. Microtubule stabilization by TPI 287 may also have potential for the treatment of neurologic disorders affected by tau protein pathology. These include tauopathies such as Alzheimer’s disease and orphan diseases, such as progressive supranuclear palsy, corticobasal degeneration, and frontotemporal dementia.
About Glioblastoma
Glioblastoma (GBM) is the most aggressive and common form of brain cancer. Five-year survival after diagnosis is about 5%. The Central Brain Tumor Registry estimates that about 26,070 primary malignant brain tumors cases will be diagnosed in the US in 2017, 46% of which will be GBM. Typical front-line treatments include stereotactic or whole brain radiotherapy plus temozolomide (Temodar®). Patients with recurrent disease are candidates for treatment with Avastin®, the last drug approved by FDA for this disease.
About Cortice Biosciences
Cortice Biosciences, Inc. is a clinical-stage drug development company pioneering novel therapies for the treatment of oncologic and neurologic disease indications with urgent unmet medical need. More information can be found at www.corticebiosciences.com.
Contact: Cortice Biosciences, Inc. 646-747-9090 [email protected]
